Abstract
Striatal cholinergic dysfunction may be important in Huntington disease (HD). We studied whether donepezil improves chorea, cognition, and quality of life (QoL) in HD. Thirty patients were randomly assigned to treatment with donepezil or placebo. At the doses studied, donepezil did not improve chorea, cognition, or QoL. Adverse events were similar between both groups. Based on this small sample study, donepezil was not an effective treatment for HD.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Chorea / etiology
-
Chorea / prevention & control*
-
Cognition Disorders / etiology
-
Cognition Disorders / prevention & control*
-
Donepezil
-
Female
-
Humans
-
Huntington Disease / complications
-
Huntington Disease / drug therapy*
-
Indans / therapeutic use*
-
Male
-
Middle Aged
-
Nootropic Agents / therapeutic use
-
Outcome Assessment, Health Care
-
Piperidines / therapeutic use*
-
Placebo Effect
-
Quality of Life*
-
Recovery of Function / drug effects*
-
Treatment Outcome
Substances
-
Indans
-
Nootropic Agents
-
Piperidines
-
Donepezil